Huntington National Bank Buys 178 Shares of BioTelemetry Inc (BEAT)

Huntington National Bank increased its stake in BioTelemetry Inc (NASDAQ:BEAT) by 35.5% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 680 shares of the medical research company’s stock after purchasing an additional 178 shares during the quarter. Huntington National Bank’s holdings in BioTelemetry were worth $43,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in BEAT. BlackRock Inc. boosted its stake in BioTelemetry by 2.7% during the fourth quarter. BlackRock Inc. now owns 5,092,773 shares of the medical research company’s stock valued at $304,141,000 after buying an additional 134,956 shares during the period. Vanguard Group Inc boosted its stake in BioTelemetry by 2.8% during the third quarter. Vanguard Group Inc now owns 1,900,117 shares of the medical research company’s stock valued at $122,462,000 after buying an additional 52,363 shares during the period. Vanguard Group Inc. boosted its stake in BioTelemetry by 2.8% during the third quarter. Vanguard Group Inc. now owns 1,900,117 shares of the medical research company’s stock valued at $122,462,000 after buying an additional 52,363 shares during the period. Geode Capital Management LLC boosted its stake in BioTelemetry by 11.8% during the fourth quarter. Geode Capital Management LLC now owns 376,618 shares of the medical research company’s stock valued at $22,490,000 after buying an additional 39,722 shares during the period. Finally, Deutsche Bank AG boosted its stake in BioTelemetry by 119.7% during the fourth quarter. Deutsche Bank AG now owns 310,751 shares of the medical research company’s stock valued at $18,556,000 after buying an additional 169,306 shares during the period. Institutional investors own 88.51% of the company’s stock.

Shares of BEAT stock opened at $54.94 on Thursday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.96 and a quick ratio of 2.81. BioTelemetry Inc has a 12-month low of $32.65 and a 12-month high of $80.92. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of 28.32 and a beta of 1.43.

BioTelemetry (NASDAQ:BEAT) last issued its quarterly earnings results on Thursday, February 21st. The medical research company reported $0.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.43 by $0.13. BioTelemetry had a return on equity of 24.46% and a net margin of 10.72%. The firm had revenue of $103.60 million during the quarter, compared to analyst estimates of $102.84 million. During the same quarter in the previous year, the company posted $0.32 earnings per share. The company’s revenue was up 13.0% compared to the same quarter last year. Equities research analysts anticipate that BioTelemetry Inc will post 1.94 earnings per share for the current fiscal year.

In other BioTelemetry news, CFO Heather C. Getz sold 64,989 shares of BioTelemetry stock in a transaction dated Friday, January 25th. The stock was sold at an average price of $70.09, for a total transaction of $4,555,079.01. Following the completion of the sale, the chief financial officer now owns 119,085 shares of the company’s stock, valued at $8,346,667.65. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Heather C. Getz sold 93,383 shares of BioTelemetry stock in a transaction dated Tuesday, January 29th. The stock was sold at an average price of $70.06, for a total value of $6,542,412.98. Following the sale, the vice president now directly owns 119,085 shares of the company’s stock, valued at approximately $8,343,095.10. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 168,962 shares of company stock valued at $11,843,134. Corporate insiders own 6.50% of the company’s stock.

Several equities research analysts recently issued reports on the company. Benchmark set a $82.00 price objective on BioTelemetry and gave the company a “buy” rating in a research note on Tuesday, April 2nd. ValuEngine lowered BioTelemetry from a “buy” rating to a “hold” rating in a research note on Monday, April 1st. Zacks Investment Research lowered BioTelemetry from a “buy” rating to a “hold” rating in a research note on Tuesday, February 12th. BidaskClub raised BioTelemetry from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 11th. Finally, Sidoti set a $95.00 price objective on BioTelemetry and gave the company a “buy” rating in a research note on Tuesday, February 5th. One research analyst has rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $80.33.

TRADEMARK VIOLATION NOTICE: “Huntington National Bank Buys 178 Shares of BioTelemetry Inc (BEAT)” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2019/04/18/huntington-national-bank-buys-178-shares-of-biotelemetry-inc-beat.html.

BioTelemetry Profile

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Read More: How is net asset value different from market price?

Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry Inc (NASDAQ:BEAT).

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit